782
SHORT REPORTS
Oral
sumatriptan in acute migraine
narcotics; regular use of narcotics; pregnancy or breastfeeding; a history of ischaemic heart disease or chest pain; hypertension (diastolic pressure above 95 mm Hg) at entry; other substantial systemic disease (eg, diabetes, asthma); and psychiatric history. Current prophylaxis was continued during the trial. The protocol or
reviewed by the relevant ethics committees and informed obtained from the patients after an explanation of the study. There were 10 men and 51 women of mean (SD) age 39 (10) years and bodyweight 67 (12) kg. At the initial interview the headache history was obtained, a physical examination carried out, and quality of life assessed. Biochemical screening, blood count and film, and an electrocardiograph were done. The study was a double-blind, randomised, paired (active/placebo), crossover design in which each patient treated four migraine headaches: two with sumatriptan 100 mg and two with matching placebo tablets. The patient was given a diary card to be completed and returned after each attack. Hospital pharmacies distributed the four tablets in four plastic containers labelled 1-4. Patients were asked to take a tablet as soon as they were confident that they were having a migraine headache and not to take any rescue medication for 2 h thereafter, at which time the effect of the treatment was judged. The patients were encouraged to return to the clinic as soon as possible after the fourth attack. The cards were then individually reviewed and any side-effects recorded. The quality of life assessments and biochemical and haematological profiles were repeated at review and further management instituted. Headache was graded as absent (0), mild (1), moderate (2), or severe (3) before and 2 h after ingestion of each treatment. For the analysis a positive result was defined as a reduction in headache grade from 3 or 2 to 0 or l. Patients asleep at 2 h were classified as unimproved. 14 patients for whom records of four treated attacks were not available (insufficient attacks, lost drug or record card, patient withdrawal, or vomiting after treatment) were excluded from the analysis. Differences between placebo-treated and sumatriptan-treated attacks were assessed with a chi-square test and evaluated at p < 0-05. was
consent was
The was
in acute assessed in a
efficacy
migraine of
oral
sumatriptan
double-blind, randomised,
placebo-controlled, crossover study of 61 patients (mean age 39 [SD 10] years). 41 completed treatment of four attacks, two with sumatriptan 100 mg and two with placebo. The response rate (reduction in headache from moderate or severe to mild or absent at 2 h) was 51% (45/89) with sumatriptan and 10% (9/93) with placebo (p
SHORT REPORTS
Oral
sumatriptan in acute migraine
narcotics; regular use of narcotics; pregnancy or breastfeeding; a history of ischaemic heart disease or chest pain; hypertension (diastolic pressure above 95 mm Hg) at entry; other substantial systemic disease (eg, diabetes, asthma); and psychiatric history. Current prophylaxis was continued during the trial. The protocol or
reviewed by the relevant ethics committees and informed obtained from the patients after an explanation of the study. There were 10 men and 51 women of mean (SD) age 39 (10) years and bodyweight 67 (12) kg. At the initial interview the headache history was obtained, a physical examination carried out, and quality of life assessed. Biochemical screening, blood count and film, and an electrocardiograph were done. The study was a double-blind, randomised, paired (active/placebo), crossover design in which each patient treated four migraine headaches: two with sumatriptan 100 mg and two with matching placebo tablets. The patient was given a diary card to be completed and returned after each attack. Hospital pharmacies distributed the four tablets in four plastic containers labelled 1-4. Patients were asked to take a tablet as soon as they were confident that they were having a migraine headache and not to take any rescue medication for 2 h thereafter, at which time the effect of the treatment was judged. The patients were encouraged to return to the clinic as soon as possible after the fourth attack. The cards were then individually reviewed and any side-effects recorded. The quality of life assessments and biochemical and haematological profiles were repeated at review and further management instituted. Headache was graded as absent (0), mild (1), moderate (2), or severe (3) before and 2 h after ingestion of each treatment. For the analysis a positive result was defined as a reduction in headache grade from 3 or 2 to 0 or l. Patients asleep at 2 h were classified as unimproved. 14 patients for whom records of four treated attacks were not available (insufficient attacks, lost drug or record card, patient withdrawal, or vomiting after treatment) were excluded from the analysis. Differences between placebo-treated and sumatriptan-treated attacks were assessed with a chi-square test and evaluated at p < 0-05. was
consent was
The was
in acute assessed in a
efficacy
migraine of
oral
sumatriptan
double-blind, randomised,
placebo-controlled, crossover study of 61 patients (mean age 39 [SD 10] years). 41 completed treatment of four attacks, two with sumatriptan 100 mg and two with placebo. The response rate (reduction in headache from moderate or severe to mild or absent at 2 h) was 51% (45/89) with sumatriptan and 10% (9/93) with placebo (p
